Nachrichten zur Eli Lilly & Co Aktie

Eli Lilly CEO says 700,000 new seniors have started GLP-1s after Medicare coverage, and 70% are on Lilly drugs

Theyre the latest metrics on how much the new Medicare coverage is expanding access to GLP-1 medicines since it launched…

Eli Lilly CEO tells CNBC one-third of new GLP-1 pill patients are taking Foundayo, as drugmaker ramps up production

Eli Lilly is trying to catch up in the GLP-1 pill market to Novo, which got a head start in…

The Next Chapter of Eli Lilly Could Be Bigger Than Investors Expect

Eli Lilly is posting 48% revenue growth while its stock sits nearly flat for the year, and that disconnect points…

CEO Chat with Dr. Christopher Burns, Chief Executive Officer and Managing Director of Amplia Therapeutics – OTC Markets Life Sciences Virtual Investor Forum

OTCQB: INNMF | ASX: ATXGreg Young: Hello, and welcome to the Life Science Investor Forum. On behalf of OTC Markets…

Eli Lilly Aktie steigt: Zepbound kehrt bei CVS zurück

Bad Marienberg (www.aktiencheck.de) - Eli Lilly-Aktienanalyse von Guggenheim: Guggenheim-Analyst Seamus Fernandez erhöht das Kursziel für die Eli Lilly-Aktie von 1.273…

Better Buy for Cautious Investors: Eli Lilly vs Costco

These companies may perform well in any market environment.…

Better Buy for Cautious Investors: Eli Lilly vs Costco

These companies may perform well in any market environment.…

Eli Lilly boosted to Buy at Berenberg as upside to 2026 guidance seen

…

Here are Tuesdays biggest analyst calls: Nvidia, Apple, AMD, Etsy, Eli Lilly, Samsara & more

Here are Tuesdays biggest calls on Wall Street.…

ANALYSE-FLASH: Berenberg hebt Eli Lilly auf 'Buy' - Ziel 1400 Dollar

HAMBURG (dpa-AFX Broker) - Die Privatbank Berenberg hat das Kursziel für Eli Lilly von 1220…

Why the Market Dipped But Eli Lilly (LLY) Gained Today

Eli Lilly (LLY) concluded the recent trading session at $1, signifying a +1.99% move from its prior days close.…

Novo CEO tells CNBC why drugmaker is rebranding, needs to rethink obesity strategy

The Danish drugmaker called the changes the beginning of a new chapter for the company, which faces stiff competition from…

Novo Nordisk May Be Poised to Outpace Eli Lilly With This Key Catalyst

Demand for Novo Nordisks new GLP-1 pill is rising quickly, while Eli Lillys new pill faces an important headwind.…

Eli Lillys Immunology Push Builds New Growth Engines Beyond GLP-1s

LLYs immunology portfolio is gaining ground, with steady revenue growth, pipeline expansion and acquisitions broadening its next wave.…

Prediction: This Is What a $5,000 Investment in Eli Lilly Will Be Worth in 2031

Hint: Its a good idea to buy the stock today.…

Top Analyst Reports for Eli Lilly, Palo Alto Networks & Texas Instruments

Eli Lilly, Palo Alto Networks and Texas Instruments benefit from strong demand, strategic moves and growth prospects despite key risks.…

Cholesterol drug setback casts doubt over multibillion-dollar race

Novartis’ failure raises the stakes for Amgen and Eli Lilly in the race to turn lower Lp(a) levels into fewer…

Heres Why Eli Lilly (LLY) Fell More Than Broader Market

The latest trading day saw Eli Lilly (LLY) settling at $1, representing a -2.21% change from its previous close.…

Eli Lilly Has Been on an Acquisition Spree. How Much Could Its Latest Deals Boost the Stock?

The big story today with Eli Lilly is its hugely successful GLP-1 drugs, but the long-term story is likely to…

Heres Why Eli Lilly (LLY) is a Strong Growth Stock

Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.…

Eli Lilly’s $100B incretin opportunity: Is more upside coming?

Eli Lilly’s $100B incretin opportunity: Is more upside coming?…

Prediction: Heres What a $5,000 Investment in Eli Lilly Could Look Like in 5 Years

Eli Lillys total return topped 367% over the past five years, largely thanks to enthusiasm for its GLP-1 offerings.…

Will Eli Lilly Split Its Stock? Heres What History Says Will Happen If It Does.

Fundamentals, not a stock split, will determine whether the bull case for Eli Lilly continues.…

Eli Lilly to Buy Immunology Biotech Merida Biosciences in $2.9B Deal

LLYs $2.9B Merida deal adds immunology assets and expands its pipeline beyond obesity and diabetes into new growth areas.…

Eli Lilly Is Acquiring Merdia Biosciences for Up to $2.88 Billion. Heres What That Means for Investors.

Hardly for the first time recently, the company is making a pricey acquisition.…

Stocks making the biggest moves midday: PG&E, Edison International, Apple, Howmet Aerospace, Eli Lilly & more

These are some of the stocks posting the largest moves midday.…

Market movers: PG&E, Aon, Eli Lilly, BioVie...

…

Eli Lilly to buy Merida Biosciences for up to $2.88B, expanding immunology pipeline

Eli Lilly and Co (NYSE:LLY) said on Monday it will acquire privately held Merida Biosciences for up to $2.88 billion…

Should Eli Lilly Investors Be Worried About a Threat From Amylyx?

Eli Lilly is currently leading the GLP-1 market, but Amylyx is seeing strong results from its GLP-1 drug candidate.…

Should Eli Lilly Investors Be Worried About a Threat From Amylyx?

Eli Lilly is currently leading the GLP-1 market, but Amylyx is seeing strong results from its GLP-1 drug candidate.…

AbbVie vs. Eli Lilly and: Which Healthcare Stock Is a Better Buy in 2026?

Eli Lillys metabolic therapies drove 45% revenue growth, but its valuation premium demands scrutiny against AbbVies defensive dividend appeal.…

Eli Lilly: FDA-Zulassung für Mounjaro zur Herz-Kreislauf-Prävention eröffnet neue Milliardenmärkte

Mounjaro und Zepbound sorgten im 2. Quartal für ein Umsatzwachstum von 48 % auf 23,0 Mrd. USD. Die FDA-Zulassung…

Eli Lilly: Kostenvorteile bei Adipositas-Therapie für das Gesundheitssystem sichern Erstattungsperspektiven

Zepbound senkt bei Patienten ab 55 Jahren die monatlichen Kosten um bis zu 607 USD. Geringere Klinikaufenthalte decken die…

Lillys GLP-1 pill hits UK pharmacies as US battle with Novo intensifies

Eli Lillys weight-loss and diabetes pill goes on sale in UK pharmacies from Monday, giving patients an oral alternative to…

Eli Lilly launches oral weight-loss pill in UK pharmacies

Eli Lilly and Co (NYSE:LLY) has launched its once-daily weight-management and diabetes pill Foundayo in UK pharmacies, offering patients an…

Eli Lilly and Novo Nordisk Cant Treat This Form of Obesity. Billionaire Stanley Druckenmiller Is Betting Rhythm Pharmaceuticals Can

Could this little-known biotech be a hidden gem?…

Billionaire Ken Griffin Just Loaded Up on Eli Lilly Stock. Should You?

Griffins Q2 move is already paying off nicely.…

Eli Lilly: Shaking Off Competition From The Dethroned Novo Nordisk

…

Stock Split Watch: Is Eli Lilly (LLY) Stock Next?

Shares recently traded at $1,280 each, so a split wouldnt be surprising.…

There’s a Black Market for Eli Lilly’s Unapproved GLP-1 Drug. Here’s Why That’s Bullish

Can anyone challenge Eli Lilly in the weight loss space?…

Could Eli Lilly Be Worth More Than SpaceX by the End of 2026?

These two stocks both have market caps of more than $1 trillion, but Eli Lillys valuation is supported by strong…

Eli Lilly and J&J bounce on new data, as software stocks give up last weeks gains

Every weekday, the Investing Club releases the Homestretch; an actionable afternoon update just in time for the last hour of…

3 ‘Vital Stories’ Films Had World Premieres At Tribeca Festival

The Tribeca and Eli Lilly "Vital Stories" program at the Tribeca Film Festival premiered short films Reconstructing Charlie, Run It…

Eli Lilly Is Building a Weight Loss Drug for Every Kind of Patient

The companys peers in the pharmaceutical industry should be worried.…

GLP-1 Demand Is Soaring. 2 Stocks That Could Benefit From This (Hint: Not Eli Lilly or Novo Nordisk)

They are way more than just GLP-1 stocks.…

ATOS: Multiple Catalysts Converge in 2H26

By David Bautz, PhDNASDAQ: ATOSREAD THE FULL ATOS RESEARCH REPORTBusiness UpdateAtossa Therapeutics, Inc. (NASDAQ: ATOS) is approaching a potentially important…

Eli Lillys GLP-1 Pricing Problem Is Actually a Growth Opportunity

The stock continues to look unstoppable.…

Can Novo Nordisks GLP-1 Pill Momentum Offset LLYs Growing Edge?

NVOs GLP-1 pills offer fresh momentum, but Eli Lillys fast-growing injectable and oral therapies threaten to widen the competitive gap.…

Lilly gains access to market that could add millions of customers

Eli Lilly (LLY) has spent 2026 defending its lead in the weight-loss drug market, mostly with injections. That approach is…

Novo Nordisk CEO defends lawsuit against Eli Lilly: Competition has to be fair

Novo Nordisk CEO defended the companys decision to sue rival Eli Lilly over its weight-loss drug advertising.…